Radiopharm Theranostics (ASX:RAD) Revenue: A$3.63 Mil (TTM As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Radiopharm Theranostics Revenue?

Radiopharm Theranostics ASX:RAD Revenue is A$3.63 Mil as of Jun. 2025. The stock has 5 warning signs investors should review.

Radiopharm Theranostics's revenue for the six months ended in Jun. 2025 was A$2.25 Mil. Its revenue for the trailing twelve months (TTM) ended in Jun. 2025 was A$3.63 Mil. Radiopharm Theranostics's Revenue per Share for the six months ended in Jun. 2025 was A$0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2025 was A$0.00.

During the past 12 months, the average Revenue per Share Growth Rate of Radiopharm Theranostics was 100.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

Radiopharm Theranostics  (ASX:RAD) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Radiopharm Theranostics Revenue Related Terms

Radiopharm Theranostics Revenue Historical Data

* Premium members only.

The historical data trend for Radiopharm Theranostics's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Radiopharm Theranostics Revenue Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Revenue
0.01 0.29 0.30 3.63

Radiopharm Theranostics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Revenue Get a 7-Day Free Trial 0.00 0.00 0.30 1.38 2.25

ASX:RAD vs VRTX, REGN, RVMD: Revenue Comparison

For the Biotechnology subindustry, Radiopharm Theranostics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Radiopharm Theranostics Revenue vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's Revenue distribution charts can be found below:

* The bar in red indicates where Radiopharm Theranostics's Revenue falls into.


Radiopharm Theranostics Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$3.63 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of A$3.63 Mil mean?
Radiopharm Theranostics (ASX:RAD) has a Revenue of A$3.63 Mil as of Jun. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on Radiopharm Theranostics and its competitors.
Is Radiopharm Theranostics' Revenue too high?
Radiopharm Theranostics' current Revenue is A$3.63 Mil.
How does Radiopharm Theranostics' Revenue compare to VRTX and REGN?
Radiopharm Theranostics' Revenue of A$3.63 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Radiopharm Theranostics and its competitors. Radiopharm Theranostics's current Revenue is A$3.63 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radiopharm Theranostics stock overvalued right now?
Radiopharm Theranostics (ASX:RAD) has a current Revenue of A$3.63 Mil. The current Revenue is A$3.63 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Radiopharm Theranostics (ASX:RAD), the current Revenue is A$3.63 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Radiopharm Theranostics Business Description

Other Exchanges RADX:USA
Address 62 Lygon Street, Suite 1, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.